Ads
related to: biologics approved for ankylosing spondylitis pain
Search results
Results from the WOW.Com Content Network
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis Intetumumab [83] [84] mab: human: CD51: solid tumors (prostate cancer, melanoma) Inolimomab: mab: mouse: CD25 (α chain of IL-2 receptor) graft versus host disease Inotuzumab ozogamicin [39] Besponsa: mab: humanized: CD22: Y: Acute ...
Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody [6] [7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis and hidradenitis suppurativa.
Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. [5] It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. [2] With AS, eye and bowel problems—as well as back pain—may occur. [2]
It has US Food and Drug Administration (FDA) approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Tumor necrosis factor alpha (TNFα) is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an ...
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
The approval was based on a Phase 3 trial data that evaluated the efficacy and safety of tofacitinib 5 mg twice daily versus placebo in 269 adult patients living with active ankylosing spondylitis ...
Ads
related to: biologics approved for ankylosing spondylitis pain